Susanne Ramey
Family · la Porte, TXNPI 1093056210
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,524 and has fallen 96.8% since, to $48 in 2025.
Across 151 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$337
- AbbVie$309
- AstraZeneca$306
- GSK$226
- Novo Nordisk$226
- Nestle Healthcare Nutrition Inc.$222
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,663100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 21 | $337 |
| AbbVie | 19 | $309 |
| AstraZeneca | 17 | $306 |
| GSK | 13 | $226 |
| Novo Nordisk | 13 | $226 |
| Nestle Healthcare Nutrition Inc. | 12 | $222 |
| Boehringer Ingelheim | 7 | $135 |
| Bayer | 6 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $99 |
| Johnson & Johnson | 6 | $95 |
| Lilly USA, LLC | 4 | $76 |
| Avanir Pharmaceuticals, Inc. | 3 | $58 |
| Jazz Pharmaceuticals Inc. | 3 | $56 |
| Heartflow, Inc. | 1 | $48 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Endo Pharmaceuticals Inc. | 3 | $39 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Vivus LLC | 2 | $33 |
| Amgen | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Boston Scientific | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Pfizer | 1 | $21 |
| Merck | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Novartis | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,663 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olmesartan Medoxomil | 16 | $1,711 |
| Atorvastatin Calcium | 57 | $1,554 |
| Losartan Potassium | 21 | $474 |
| Pravastatin Sodium | 13 | $457 |
| Omeprazole | 14 | $405 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $328 |
| Lisinopril | 22 | $225 |
| Pantoprazole Sodium | 11 | $202 |
| Amlodipine Besylate | 29 | $190 |
| Metformin Hcl | 20 | $173 |
| Alendronate Sodium | 11 | $147 |
| Methylprednisolone | 12 | $64 |
| Levothyroxine Sodium | 14 | $58 |
Paid to pharmacies, not to this prescriber.
Other family in la Porte
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.